In a testosterone-induced BPH mouse model, CXCL13 treatment enhanced CD4<sup>+</sup> T cell infiltration and reduced epithelial senescence, while CD4<sup>+</sup> T cell depletion reversed these effects. Here, CD4 is linked to benign prostatic hyperplasia.